Perceptive Advisors

SilaGene, Inc. is a biotechnology company based in Hillsborough, New Jersey, founded in 2008. The company specializes in the development of U1 adaptors that hold therapeutic potential for various diseases, particularly in the treatment of different types of cancers. Its innovative technology serves as a gene silencing tool, which enhances the research of gene function in both cell cultures and in vivo settings. By addressing the limitations of existing gene silencing technologies, SilaGene aims to provide effective treatment options for patients.

Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure (CHF) in the United States and Europe. The company specializes in Cardiac Contractility Modulation therapy, utilizing its proprietary technology to administer non-excitatory electrical impulses that enhance cardiac performance. The Optimizer III device, which is CE marked, delivers these impulses to the ventricular septum during the myocardial absolute refractory period. Impulse Dynamics conducts clinical trials to evaluate the safety and efficacy of its treatments and collaborates with universities and hospitals for research programs. Founded in 1996 and headquartered in Willemstad, Curacao, the company also has offices in New York and Hong Kong, along with product development centers in New Jersey and Israel.

Agile Therapeutics, Inc. is a women's healthcare company dedicated to developing and commercializing prescription contraceptive products. The company’s lead product, Twirla, is a once-weekly transdermal contraceptive patch that delivers a low dose of levonorgestrel and ethinyl estradiol. Agile Therapeutics is also advancing a pipeline of related products, including various line extensions of Twirla and additional transdermal contraceptive options. These include regimens designed to extend menstrual cycles or provide shorter and lighter periods, as well as a progestin-only patch intended for women who cannot or prefer not to use estrogen. Founded in 1997 and headquartered in Princeton, New Jersey, Agile Therapeutics aims to address the unmet healthcare needs of women through innovative contraceptive solutions.

Clover Health is a health insurance company that specializes in providing Medicare Advantage plans for senior citizens. Founded in 2014 and headquartered in San Francisco, California, the company also has offices in several states, including New Jersey, Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Clover Health operates a Preferred Provider Organization (PPO) platform that aims to enhance the quality of life for its members through patient-centered analytics and dedicated care management. By utilizing advanced analytics and custom software, Clover Health directs its clinical staff to proactively address gaps in care, focusing on preventive measures and chronic disease management. Its approach not only aims to improve health outcomes but also seeks to reduce unnecessary healthcare spending. The company primarily generates revenue through its insurance segment, which offers both PPO and Health Maintenance Organization (HMO) plans.

Foamix Pharmaceuticals Inc. a pharmaceutical company, engages in development and commercialization of proprietary, innovative, and differentiated topical drugs for dermatological conditions. It offers Molecule Stabilizing Technology (MST) platform. The company was incorporated in 2014 and is based in Bridgewater, New Jersey. Foamix Pharmaceuticals Inc. operates as a subsidiary of Menlo Therapeutics Inc.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company's product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin products indicated for primary humoral immunodeficiency, as well as Nabi-HB, which treats acute exposure to Hepatitis B. ADMA also has a pipeline of therapeutics targeting infections such as S. pneumonia. To support its production, ADMA operates FDA-licensed source plasma collection facilities, known as ADMA BioCenters, which supply plasma for its products. The company distributes its offerings through independent distributors, sales agents, and specialty pharmacies. Founded in 2004 and headquartered in Ramsey, New Jersey, ADMA Biologics is dedicated to serving niche patient populations, particularly those who are immune-compromised due to underlying conditions or medical treatments.

Vyome Therapeutics focuses on developing innovative treatments for antibiotic-resistant acne and other pathogens through a unique pipeline of antibiotics designed to slow the development of resistance. The company's product portfolio includes VB 1953, its lead molecule targeting the significant unmet needs in the resistant acne market, along with various anti-dandruff products such as VB 001 (a leave-on scalp care treatment), VB 2421 (a hair gel), VB 3222 (a wash-off shampoo), and VB 7731 (a Ketoconazole emulsion gel). Established in 2010 and based in Princeton, New Jersey, the company incorporates advanced research and development capabilities, including formulation, analytical, and clinical divisions. Vyome's management team boasts extensive expertise in dermatology and has a proven track record of successfully launching numerous products. The firm is committed to addressing refractory skin conditions and aims to bring its innovative therapies to market effectively.

Vyome Therapeutics focuses on developing innovative treatments for antibiotic-resistant acne and other pathogens through a unique pipeline of antibiotics designed to slow the development of resistance. The company's product portfolio includes VB 1953, its lead molecule targeting the significant unmet needs in the resistant acne market, along with various anti-dandruff products such as VB 001 (a leave-on scalp care treatment), VB 2421 (a hair gel), VB 3222 (a wash-off shampoo), and VB 7731 (a Ketoconazole emulsion gel). Established in 2010 and based in Princeton, New Jersey, the company incorporates advanced research and development capabilities, including formulation, analytical, and clinical divisions. Vyome's management team boasts extensive expertise in dermatology and has a proven track record of successfully launching numerous products. The firm is committed to addressing refractory skin conditions and aims to bring its innovative therapies to market effectively.

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative medicines to meet unmet medical needs both in the United States and internationally. The company offers several marketed products, including Sympazan, an oral soluble film for treating Lennox-Gastaut syndrome; Suboxone, a sublingual film for opioid dependence; and Zuplenz, an oral soluble film for nausea and vomiting related to chemotherapy and post-operative recovery. Additionally, Aquestive's proprietary product candidates include Libervant, a buccal film for epileptic seizures, and Exservan, an oral film for Amyotrophic Lateral Sclerosis. The company's pipeline also features AQST-108, a sublingual film for anaphylaxis, AQST-305 for acromegaly, and APL-130277 for Parkinson's disease. Established in 2004 and headquartered in Warren, New Jersey, Aquestive Therapeutics leverages its proprietary technologies to address complex healthcare challenges and partners with other pharmaceutical companies to enhance drug delivery methods.

Arno Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative treatments for cancer and other life-threatening diseases. The company's pipeline features several drug candidates, including Onapristone, a type 1 anti-progestin hormone blocker currently in Phase I/II clinical studies aimed at treating various solid tumors, including breast and endometrial cancers in post-menopausal women, as well as advanced castration-resistant prostate cancer in men. Another candidate, AR-12, has completed Phase I clinical studies for the treatment of solid tumors and hematological malignancies, and is also undergoing pre-clinical studies for various anti-microbial targets. Additionally, AR-42, an orally available therapy, is in Phase I investigator-initiated clinical studies for hematological malignancies and solid tumors. Arno Therapeutics has established license agreements with multiple institutions and a co-development agreement with Leica Biosystems Newcastle Ltd., and is headquartered in Flemington, New Jersey.

Arno Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative treatments for cancer and other life-threatening diseases. The company's pipeline features several drug candidates, including Onapristone, a type 1 anti-progestin hormone blocker currently in Phase I/II clinical studies aimed at treating various solid tumors, including breast and endometrial cancers in post-menopausal women, as well as advanced castration-resistant prostate cancer in men. Another candidate, AR-12, has completed Phase I clinical studies for the treatment of solid tumors and hematological malignancies, and is also undergoing pre-clinical studies for various anti-microbial targets. Additionally, AR-42, an orally available therapy, is in Phase I investigator-initiated clinical studies for hematological malignancies and solid tumors. Arno Therapeutics has established license agreements with multiple institutions and a co-development agreement with Leica Biosystems Newcastle Ltd., and is headquartered in Flemington, New Jersey.

Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.

Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.

Champions Oncology, Inc. specializes in developing technology solutions and products aimed at personalizing the treatment of cancer. The company employs its Tumorgraft Technology Platform, which involves implanting human tumors in immune-deficient mice, to provide Personalized Oncology Solutions (POS). This platform enables physicians to tailor treatment options based on specific tumor data obtained from drug panels. Additionally, Champions Oncology offers Translational Oncology Solutions to assist pharmaceutical and biotechnology companies in their drug development processes. The company's product offerings include TumorGraft implants and drug panels that evaluate the response of a patient's tumor to various oncology drugs or combinations. Champions Oncology markets its products through online channels, referrals, and a dedicated sales team. Founded by leading experts in cancer research and treatment, the company is headquartered in Hackensack, New Jersey, and was incorporated in 1985.

Arno Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative treatments for cancer and other life-threatening diseases. The company's pipeline features several drug candidates, including Onapristone, a type 1 anti-progestin hormone blocker currently in Phase I/II clinical studies aimed at treating various solid tumors, including breast and endometrial cancers in post-menopausal women, as well as advanced castration-resistant prostate cancer in men. Another candidate, AR-12, has completed Phase I clinical studies for the treatment of solid tumors and hematological malignancies, and is also undergoing pre-clinical studies for various anti-microbial targets. Additionally, AR-42, an orally available therapy, is in Phase I investigator-initiated clinical studies for hematological malignancies and solid tumors. Arno Therapeutics has established license agreements with multiple institutions and a co-development agreement with Leica Biosystems Newcastle Ltd., and is headquartered in Flemington, New Jersey.